Samil Pharmaceutical2021 Investor Relations
(K-IFRS) . . ‘ ’ . ‘ ’ , . , .
2
Chapter 2.
03.
Chapter 4.
4
66.9
• : 216
• : 216
• : , , , ,
360º Human Care , , Total Care, Life Care

1975~1997
1998~2015
1969. (Boots)

1974.

2021. Lorecivivint
CMO


,
Chapter 2.
7
8



50%
28%
4%
915 941
1,226
10
2021 2021
(: ) (: )
3,645 3,822
, 21%
(: )
)
04
04
1,381
1,555
(: ,)
(: )
04
392
359
487
442
(:)
14
83
108
74
2020 2021 (: )

05
Chapter 3.
- CMO
-
- CMO
-
- –
- –
03.
- CAPA
-
16
20.0 21.4 22.4 23.6 24.9
26.3 20.3
22.5 25.1
28.1 31.7

) Frost & Sullivan, ) 2016
(: )
CMO
CMO 2015 727 2020 1,087 8.4%
CMO
CDMO
CDMO
SK Capital Catalent (2021 1)
Lonza, (2021 1)
18
(’20)
2.5 EU GMP
‘Systane® Hydration PF’ (‘20)
2.2 EU GMP
(Lumify), (Soothe XP), (Ocuvite) OTC
‘TJO-087’ 3 (’20)
2017 Abbott 3
(HU-007) 3 IND (‘19)
TRACON Pharma wAMD ‘DE-122’ (‘20)
3 ‘TFC-003’ 3 (‘20)



CMO 01
GMP
19
2009
2017
2018
1986
2016

1.0 1.1 1.2 1.3 1.5 1.6 1.8 1.9 2.0
2.8 3.1 3.5



-
(: ) (: )
20
) ,


- 1.07% ( 5 CAGR)

21
67,989
(: )

22

FTA
(: )


23

Stage 1. 2018 Stage 2. 2019~2022 Stage 3. 2022~2024 Stage 4. 2023~2026


25,008.5 m2
24

0.5 bottle
Isolator (barrier system)
Franz ziel (Germany)
• Multi-dose Line Isolator • Isolator • Material (bottle, cap, dropper) • Isolator (VHP) •
Bottle Filing Machine
Groninger (Germany)
• 250 bottle / min • • system • (CIP), (SIP)
(Single-dose)
2
BFS Rommelag (Germany)
• Rotary-type (Blow-Fill-Seal) • system • 30,000 ampoule/hour
03

Chapter 4.
02. Pipeline - NASH
- NASH (2 )
- Galmed AramcholTM
- AramcholTM 2b
- AramcholTM 3/4(ARMOR)
03. Pipeline - Lorecivivint
-
R&D Pipeline
Research Pre-Clinical Phase 1 Phase 2 Phase 3
ZVT eye drop
XDA eye drop
KSR-001 eye drop

29
2B/3
( )
• Rebamipide diquafosol
•
SIF-1002
• -3
•

• cetirizine
•
SIF-2002
•
•
•
SIN-2001 B 1 IND

• B

•
• B

30
0.7
3.8
9.2
17.1
24.0
28.2
Failed
) 2020 7
Cenicriviroc CCR2/5 antagonist 3 4Q20 AURORA Topline
Resmetirom(MGL-3196) THR-β agonist 3 2021 MAESTRO-NAFLD-1 Topline data
Aramchol SCD-1 modulator 3 4Q21 3(ARMOR Open-label)
Belapectin (GR-MD-02) galectin-3 inhibitor 2b/3 2020 6
Ozempic(semaglutide) GLP-1 agonist 3 2021 3
MSDC-0602K Insulin sensitizer 3 2b (2019 11)
Lanifibranor (IVA337) pan-PPAR agonist 2b 2b (2020), 2021 3
GS-9674 FXR agonist 2b 2018 11
GS-0976 ACC Inhibitor 2b 2017 10
Tropifexor (LJN452) FXR agonist 2 2 (2019 11)
Pegbelfermin FGF21 Inhibitor 2a 2 (2018 12)
PF-05221304 ACC Inhibitor 2a 2 (3Q17), 2
Ocaliva (OCA) FXR agonist 3 (2019 2), FDA (20206)
Elafibranor (GFT505) PPAR α/δ agonist 3 (2020 7)
Selonsertib (GS-4997) ASK1 inhibitor STELLAR 4, STELLAR 3 (2019 2, 4)
Emricasan (IDN-6556) Caspase inhibitor LF 2b (2019 6), PH 2b (2018 12)
Volixibat (SHP626) ASBT inhibitor 2018 7 2b
EDP-035 FXR agonist 2b (2019 9)
31
(: Zydus Cadila Saroglitazar 2020 5 )
2016 7 ‘(Galmed)’ Aramchol
Aramchol 2b 3 (2019.09.27)
3 Open-Label
Upfront payment US$2.0mn ( )
Milestone Payments US$6.0mn ( US$1.5mn )
Royalty
Option ARREST

NASH 50~100 Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 2007;47:239-244.
32
NASH Aramchol
) Galmed Pharmaceuticals, NASH Summit 2019
33
02
Aramchol 2
3 150 Open-Label ( )
2Q21 FDA Type C Aramchol 2022 1Q
) Galmed Pharmaceuticals, 2021 1, “KOL Symposium & Pipeline Update”
34
35
) ,
()
3,529
3,731
3,960
4,225
4,534
()
36
Lorecivivint (Biosplice) (/) ()
2023 2017.11 2012.01
Wnt inhibitor TGF-β1
1
(300 ) 700() 1,000()
K&L grade 2~3 K&L grade 3 K&L grade 4
, ,
-- (2019.07.09) --

( )
1. DMOAD , DMOAD
2. K&L grade 2 ( )
(K&L grade 2~3 65% )
3.
4. punching
DMOAD Unmet Needs
37
Biosplice Lorecivivint 03
Lorecivivint 3 2021 FDA
Upfront payment US$3.0mn
Royalty
/ 3(1): STRIDES-1(SM04690-OA-10, : 726, NCT04385303) 3(2): STRIDES-X-ray(SM04690-OA-11, : 725, NCT03928184) → 2021 3 → 2021 4 Top-line

DMOAD(disease-modifying osteoarthritis drug)
1) Wnt pathway inhibitor FDA
2) Unmet needs ( /)
3)
DMOAD
DMOAD
38
Wnt Pathway 03
) Samumed, American College of Rheumatology (ACR) | November 08 - 13, 2019

1
2
3
Wnt
4
39
40
( )

(, (JSW) )
2020 5 ~ 2021 4 2019 5~2021 6
726 725

X-ray
NCT04385303 https://clinicaltrials.gov/ct2/show/NCT04385303
3 2021
Appendix
41


(: )


- 5,591 17,230 17,230
(: )

2021 Investor Relations